Dexcom Raises Another Billion, But Why?
The company’s cash balance at the end of last quarter was more than enough to weather most storms – so why has Dexcom raised more money?
You may also be interested in...
Insulet and EOFlow have been locked in a legal dispute for more than two months now, however it seems EOFlow may be on the back foot, after having an injunction made against it. This could have major implications for the wider diabetes sector, as a whole.
News We’re Watching: Medtronic To Buy EOFLow, Neuralink Cleared For Human Trials, NICE Backs Genetic Tests
This week, Medtronic said it would pay $738m for insulin patch firm EOFlow; Neuralink got an FDA OK for first-in-human trials; and UK agency NICE backed genetic tests for stroke patients and digital therapeutics for mental health conditions.
Earlier than expected, but still after a more than three year wait, the company has obtained FDA approval for its flagship insulin delivery system.